SecBot SecBot

ZTS drug pipeline

Zoetis Inc. · 5 rated drugs
$83.82
+1.0% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
5
1 bearish · 4 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (10 mg/mL); Research/Preclinical (4% formulation)
Time to marketThe standard 10 mg/mL formulation is already on the market. The 4% concentrated formulation appears to be an experimental/research-stage product with no publicly disclosed regulatory submission or commercialization timeline.

Alfaxan Multidose 4% alfaxalone Updated Nov 7

What to watch

Alfaxan Multidose 4% has no scheduled regulatory decision or pivotal readout in the next 12 months. The standard 10 mg/mL formulation is already marketed. Watch for any FDA submission or label expansion for the 4% concentrated formulation, but none is currently visible. Zoetis's stock moves on company-wide earnings and its large dermatology/parasiticide portfolio, not on this single anesthetic product.

Bull case
  • Alfaxalone is a well-established veterinary anesthetic with a strong safety profile and is the leading anesthetic product in its class globally.
  • The 4% concentrated formulation allows smaller injection volumes, which is advantageous for wildlife and exotic animal sedation where large volumes are impractical.
  • Zoetis acquired Jurox (and Alfaxan) in 2022, and the product benefits from Zoetis's global commercial infrastructure and distribution network.
Bear case
  • The 4% concentrated formulation appears to still be in the research phase with no clear FDA submission or commercialization timeline visible.
  • Alfaxan is a very small product within Zoetis's massive portfolio; Zoetis has dozens of products with over $100M in annual revenue, making Alfaxan immaterial to the stock's performance.
  • Zoetis faces competitive pressure in its core dermatology franchise (Apoquel, Cytopoint), which are the real value drivers, and the company's Q3 2026 revenue declined 1% year-over-year.
▼ bearish
Impact
PhaseApproved
Time to marketAlready on market since 2008

Convenia cefovecin sodium Updated Sep 4

What to watch

Convenia is a mature, approved product facing generic erosion, a known headwind already priced into ZTS's ~50% decline from its 52-week high. The next meaningful catalyst for ZTS is its quarterly earnings (next likely in late October/November 2026), where Convenia generic impact will be visible in the companion animal segment. Investors should watch for further margin compression and market share loss to Dechra's Solovecin.

Bull case
  • Convenia's single-dose convenience and long duration of action (up to 14 days) create brand loyalty among veterinarians, potentially slowing generic adoption
  • Zoetis is a diversified animal health giant, Convenia is just one product in a portfolio spanning livestock, poultry, fish, and companion animals, so generic erosion is manageable
  • Analyst consensus still shows a mean price target of $96 (23% upside from ~$76), with 12 Buy/Strong Buy ratings vs 12 Hold and 0 Sell
Bear case
  • FDA approved the first generic cefovecin sodium injection on June 24, 2025, and Dechra launched Solovecin as a bioequivalent generic, direct competition will erode Convenia's pricing and market share
  • Convenia had been a Zoetis blockbuster for over 15 years; generic entry represents a material revenue headwind for the companion animal segment
  • ZTS stock has fallen ~51% from its 52-week high of $155 to ~$76, reflecting market concerns about generic competition and broader headwinds
● neutral
Impact
PhaseApproved
Time to marketAlready approved and launched (FDA approval received October 20, 2026). The product is commercially available in the U.S. market.

Convenia RTU cefovecin injectable suspension Updated Nov 7

What to watch

Convenia RTU was approved by the FDA on October 20, 2026, so the binary catalyst has passed. The next thing to watch is how quickly the product gains traction in the veterinary market and whether it helps stabilize Zoetis's dermatology portfolio, which declined 16% in Q3 2026 due to generic competition on the original Convenia and other pressures. Adoption metrics may be discussed on the Q4 2026 earnings call.

Bull case
  • The RTU formulation is a higher-concentration, ready-to-use version that eliminates the reconstitution step and reduces injection volume, making treatment more practical for medium and large dogs and potentially expanding the addressable market.
  • Convenia RTU builds on 18+ years of real-world clinical experience with the original Convenia (approved 2008), lowering adoption risk among veterinarians.
  • Zoetis management highlighted the approval as a key 2026 milestone achieved ahead of schedule, and the product helps defend against generic erosion of the original Convenia franchise.
Bear case
  • The original Convenia is facing active generic competition that pressured Zoetis's dermatology portfolio down 16% in Q3 2026, and the RTU formulation may not fully offset those losses.
  • Zoetis is a large, diversified animal health company (market cap ~$34B) where Convenia RTU is a minor line extension; even strong uptake would have a negligible impact on the overall stock.
  • Jefferies downgraded ZTS from Buy to Hold on October 20, 2026 (the same day as the approval), reflecting broader concerns about companion animal headwinds.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and launched in the US and Mexico (Q3 2026) and EU (Q2 2026). Commercial availability is underway.

Fostera PRRS Needle-free microdose porcine reproductive and respiratory syndrome vaccine, live modified virus Updated Nov 7

What to watch

The Fostera PRRS Needle-free microdose has already been approved in the US and Mexico (Q3 2026) and in the EU as Suvaxyn PRRS Needle-Free Microdose (Q2 2026). No further binary regulatory catalysts remain for this specific product. Watch for commercial adoption metrics in Zoetis's livestock segment in future quarterly reports, but this is a minor product line extension within a diversified portfolio.

Bull case
  • Needle-free intramuscular delivery is a meaningful innovation for swine producers, reducing labor, needle-stick injuries, and vaccine administration stress on pigs. This could drive adoption among large-scale producers.
  • The product received simultaneous approvals in the US and Mexico, and a related version (Suvaxyn PRRS Needle-Free Microdose) was approved in the EU in Q2 2026, suggesting a coordinated global rollout strategy.
  • Zoetis's US livestock revenue rose 5% in Q3 2026, and the company raised its full-year 2026 adjusted EPS guidance, indicating overall business momentum that this product can contribute to.
Bear case
  • Fostera PRRS is a mature product; the needle-free microdose is a formulation/delivery upgrade, not a new blockbuster. Zoetis's Q3 2026 total revenue fell 1% year-over-year to $2.4B, and the stock dropped 3.3% on the earnings day despite the approval announcement.
  • The PRRS vaccine market is competitive, with multiple modified-live and killed vaccines available from animal health rivals. Differentiation on needle-free delivery alone may not drive significant market share gains.
  • Zoetis is a $36B+ market cap diversified animal health company; a single livestock vaccine formulation upgrade is immaterial to the overall financial picture.
● neutral
Impact
PhaseApproved/Marketed
Time to marketAlready on the market. The product has been commercially available in the U.S. since at least 2016 and is also sold in Brazil, New Zealand, and other international markets.

Vanguard B Oral Bordetella bronchiseptica vaccine avirulent live culture Updated Nov 7

What to watch

Vanguard B Oral is a mature, already-commercialized product with no pending regulatory decision or pivotal readout. The next incremental catalyst would be additional geographic label expansions (like the recent Brazil claim), but these are routine commercial updates, not stock-moving binary events. For Zoetis investors, the product is a small contributor within a $9.5B+ revenue portfolio; watch Zoetis's quarterly companion-animal vaccine franchise trends instead.

Bull case
  • Vanguard B Oral is the only oral Bordetella vaccine with a USDA-verified 1-year duration of immunity, a differentiating claim versus some competing products.
  • The product recently received an additional label claim in Brazil (announced November 5, 2026), expanding its addressable market in a major pet-owning region.
  • A peer-reviewed study (American Journal of Veterinary Research, 2026) demonstrated a rapid 7-day onset of protective immunity, supporting the product's clinical profile.
Bear case
  • Vanguard B Oral faces competition from multiple alternative Bordetella vaccine formats: Zoetis's own newer Vanguard Recombishield injectable (launched November 2025), Merck's Nobivac Intra-Trac Oral Bb, and Elanco's TruCan B Oral, all targeting the same kennel-cough market.
  • As a mature product in a large portfolio, Vanguard B Oral is not material enough to Zoetis's $9.5B+ revenue base to drive the stock on its own, so even positive label expansions have limited share-price impact.
  • The product is a live-attenuated vaccine requiring cold-chain shipping, which adds logistical complexity and cost versus some competitors.